Erin Mershon

News Editor

Erin Mershon is a STAT news editor and previously served as senior Washington correspondent. She's written extensively on policymaking issues for CQ Roll Call, Politico Pro, the National Journal and several other news outlets. A graduate of Kenyon College in Ohio, Erin won a 2017 Association of Health Care Journalists Fellowship to report on health insurance challenges in rural areas across the U.S. When she's not working, Erin is usually indulging her obsession with ballet, either at a Kennedy Center performance or a beginner class.

Politics

Erin Mershon

News Editor

It’s official: parts of the government, including FDA, shut down early Saturday

Archived chat: The midterms are over. What’s next for health and medicine?

Trump administration proposes further cuts to drug discount program that helps hospitals

Senate committee advances bill to eliminate ‘gag clauses’ limiting disclosures on drug prices

Unpacking the bold — and the bluster — in Trump’s plan to bring down drug prices

HHS opens door to possibility of importing some drugs to drive down prices

FDA’s Gottlieb slams drug makers for stalling release of biosimilars

Appeals court rejects hospital industry’s challenge on 340B changes

What Pfizer, Trump, and consumers got out of a surprising deal — and what they didn’t

In subtle mixing of messages, the drug industry tries to press Congress to lift burden for more drug costs

Azar makes case for revamping hospital drug discounts — to hospitals defending them

Top Democrat demands PhRMA, BIO do more on gender issues after party with topless dancers

Mass. gets a thumbs-down on negotiating Medicaid prices, but Oklahoma wins on ‘value’ rebates

As the drug industry eyes the burgeoning biosimilar market, its united front is starting to crack

Key lawmaker calls for more scrutiny of hospitals using drug discount program — but no broader changes

Bill to encourage generic-drug development passes a key hurdle

Azar says HHS could change or eliminate Medicare drug rebates without Congress

Drug makers considering ‘substantial’ decreases in prices, Azar says

Erin Mershon

News Editor

Sign up for our Daily Recap newsletter